Annex to press release 2 April 2015

amounts in € million	2014 Q1	Q2	Q3	Q4	Year
Nutrition					
Net sales	1,047	1,073	1,091	1,124	4,335
EBITDA	203	222	225	200	850
EBIT	143	165	163	125	596
Performance Materials					
Net sales	589	615	638	618	2,460
EBITDA	71	85	87	80	323
EBIT	43	55	55	51	204
Innovation Center					
Net sales	34	38	40	42	154
EBITDA	-6	-5	-4	-3	-18
EBIT	-14	-12	-10	-9	-45
Corporate Activities					
Net sales	22	28	25	27	102
EBITDA	-29	-38	-27	-23	-117
EBIT	-39	-51	-39	-39	-168
Continuing Operations					
Net sales	1,692	1,754	1,794	1,811	7,051
EBITDA	239	264	281	254	1,038
EBIT	133	157	169	128	587
Discontinued					
Net sales	606	534	529	563	2,232
EBITDA	31	29	34	34	128
EBIT	11	8	14	-3	30
Total DSM					
Net sales	2,298	2,288	2,323	2,374	9,283
EBITDA	270	293	315	288	1,166
EBIT	144	165	183	125	617

Key figures (continuing operations, before exceptional items)	
- Capex cash	451
- Operating working capital	1,903
- OWC / net sales	26.3%
- ROCE	8.2%
EBIT (continuing operations, before exceptional items)	587
Finex	-102
Tax	-84
Result associates	8
Group net profit	409
Net profit non-controlling interests	-5
Net profit attributable to shareholders Kon. DSM NV	414

These comparative figures reflect the reclassification of the Polymer Intermediates cluster and the DSM Composite Resins business group to discontinued operations after the announced partnership for these businesses with CVC Capital Partners (CVC). DSM's Corporate Activities are also restated, since DSM's 65% stake in Sitech Services will be transferred as a result of the partnership with CVC. The restatement also reflects the sale of DSM Synres to Standard Investment and Euroresins to Cathay Investments

DSM
BRIGHT SCIENCE. BRIGHTER LIVING.

DISCLAIMER
This document may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. Examples of forward-looking statements include statements made or implied about the company's strategy, estimates of sales growth, financial results, cost savings and future developments in its existing businesses as well as the impact of future acquisitions, and the company's financial position. These statements can be management estimates based on information provided by specialized agencies or advisors.
DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause the company's actual performance and position to differ materially from these statements. These factors include, but are not limited to, macro-economic,market and business trends and conditions, (low-cost) competition, legal claims, the company's ability to protect intellectual property, changes in legislation, changes in exchange and interest rates, changes in tax rates, pension costs, raw material and energy prices, employee costs, the implementation of the company's strategy, the company's ability to identify and complete acquisitions and to successfully integrate acquired companies, the company's ability to realize planned divestments, savings, restructuring or benefits, the company's ability to identify, develop and successfully commercialize new products, markets or technologies, economic and/or political changes and other developments in countries and markets in which DSM operates. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the 'Risk Management' chapter of DSM's Integrated Annual Report 2014. As a result, DSM's actual future performance, position and/or financial results may differ materially from the plans, goals and expectations set forth in such forward looking statements. DSM has no obligation to update the statements contained in this document, unless required by law.